S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10

Tricida Stock Forecast, Price & News

-0.10 (-1.02%)
(As of 01/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.50 million shs
Average Volume
365,265 shs
Market Capitalization
$490.86 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

Tricida logo

About Tricida

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker in 2013 and is headquartered in South San Francisco, CA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$2.17 per share


Net Income
$-264.79 million
Pretax Margin




Free Float
Market Cap
$490.86 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.33 out of 5 stars

Medical Sector

256th out of 1,417 stocks

Pharmaceutical Preparations Industry

111th out of 683 stocks

Analyst Opinion: 3.3Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -

Tricida (NASDAQ:TCDA) Frequently Asked Questions

Is Tricida a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Tricida stock.
View analyst ratings for Tricida
or view top-rated stocks.

How has Tricida's stock price been impacted by Coronavirus (COVID-19)?

Tricida's stock was trading at $28.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TCDA stock has decreased by 65.3% and is now trading at $9.73.
View which stocks have been most impacted by COVID-19

Are investors shorting Tricida?

Tricida saw a increase in short interest in December. As of December 31st, there was short interest totaling 1,430,000 shares, an increase of 16.3% from the December 15th total of 1,230,000 shares. Based on an average daily trading volume, of 311,900 shares, the days-to-cover ratio is presently 4.6 days. Currently, 4.5% of the company's shares are short sold.
View Tricida's Short Interest

When is Tricida's next earnings date?

Tricida is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Tricida

How were Tricida's earnings last quarter?

Tricida, Inc. (NASDAQ:TCDA) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.09. During the same quarter in the prior year, the business posted ($1.55) EPS.
View Tricida's earnings history

What price target have analysts set for TCDA?

2 Wall Street analysts have issued 12 month price objectives for Tricida's shares. Their forecasts range from $7.00 to $20.00. On average, they expect Tricida's stock price to reach $13.50 in the next year. This suggests a possible upside of 38.7% from the stock's current price.
View analysts' price targets for Tricida
or view top-rated stocks among Wall Street analysts.

Who are Tricida's key executives?

Tricida's management team includes the following people:
  • Gerrit Klaerner, President, Chief Executive Officer & Director
  • Geoffrey M. Parker, Executive VP, Chief Operating & Financial Officer
  • Dawn Parsell, Executive Vice President-Clinical Development
  • Elizabeth A. Faust, Executive Vice President-Medical Affairs
  • Robert McKague, Chief Compliance Officer, EVP & General Counsel

What is Gerrit Klaerner's approval rating as Tricida's CEO?

2 employees have rated Tricida CEO Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among Tricida's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).

When did Tricida IPO?

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Who are Tricida's major shareholders?

Tricida's stock is owned by a variety of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.06%) and Belvedere Trading LLC (0.00%). Company insiders that own Tricida stock include Dawn Parsell Otto, Geoffrey M Parker, Gerrit Klaerner, Kurtis R Kurimsky, Robert Mckague, Sandra I Coufal and Wilhelm Stahl.
View institutional ownership trends for Tricida

Which major investors are selling Tricida stock?

TCDA stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. Company insiders that have sold Tricida company stock in the last year include Gerrit Klaerner, Kurtis R Kurimsky, and Sandra I Coufal.
View insider buying and selling activity for Tricida
or view top insider-selling stocks.

Which major investors are buying Tricida stock?

TCDA stock was acquired by a variety of institutional investors in the last quarter, including Belvedere Trading LLC. Company insiders that have bought Tricida stock in the last two years include Geoffrey M Parker, and Robert Mckague.
View insider buying and selling activity for Tricida
or or view top insider-buying stocks.

How do I buy shares of Tricida?

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $9.73.

How much money does Tricida make?

Tricida has a market capitalization of $490.86 million. The company earns $-264.79 million in net income (profit) each year or ($3.61) on an earnings per share basis.

How many employees does Tricida have?

Tricida employs 64 workers across the globe.

What is Tricida's official website?

The official website for Tricida is www.tricida.com.

Where are Tricida's headquarters?

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (415) 429-7800 or via email at [email protected].

This page was last updated on 1/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.